The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: CIHR

Monday Biotech Deal Review: July 26, 2010

Things were interesting for Forbes Medi-Tech (or at least its creditors), which saw a new bidder emerge for its assets. A few placements and other deals closed, some lower than expected. See who made it through the heat without wilting this week after the jump…

Grand Challenges Canada to Mobilize $225 Million Over 5 Years For Global Health

A new nonprofit organization called Grand Challenges Canada has been formed to deploy the Canadian government’s $225 million Development Innovation Fund. In a fabulous marriage of theory and practice, Grand Challenges will be run by Peter Singer, who is also the Director of the McLaughlin-Rotman Centre for Global Health. It also draws on an impressive international scientific advisory board.

The program will identify and launch five “grand challenges” over a 5-year period. The first is

“to create a new class of point-of-care (POC) diagnostics that will be easy to use, low cost, multiplexed and able to assess disease stage and provide information on prognosis.”

Information on the RFP, policies and forms to apply for funding are here, and the deadline for this round of applications is July 12, 2010 at 11:59 pm EST.

Grand Challenges Canada is independent, but is being run in partnership with International Development Research Centre (IDRC), the Canadian Institutes of Health Research (CIHR), the McLaughlin-Rotman Centre for Global Health and with support from the Bill & Melinda Gates Foundation.

Bookmark and Share

PubMed Central Canada Opens for Business: Free Online Access to Life Sciences Journals

The PubMed Central Canada project (noted here last July) is now open for business at http://pubmedcentralcanada.ca/ This collaboration — between the NRC’s Canada Institute for Scientific and Technical Information, the Canadian Institutes of Health Research (CIHR), and the U.S. National Library of Medicine — “aims to provide a freely accessible, Canada-based archive of biomedical and health research findings.”

It also allows CIHR-funded researchers to comply with the Institute’s Policy on Access to Research Outputs, which requires grantees to make their peer-reviewed publications freely accessible online within six months of publication. There’s a login-based manuscript submission system, but since I’m not CIHR funded, I can’t check it out. If you are, and you do, let us know how it works.

Bookmark and Share

Monday Biotech Deal Review: March 8, 2010

A busy week in Canadian deals, with Paladin Labs in a global transaction with SpePharm; M&A activity from therapeutics and consulting companies; the last of the SIFT/SR&ED deals; over $20 million of new offerings from BioSign, Bradmer and YM; government funding for Medicago and Isotechnika; a new standby equity deal from Yorkville for Allon; and the closing of the first deal of the rest of BioMS’ new life. Read more of this post

More Highlights in Canada’s 2010 Federal Budget For Biotech, Venture Capital and Innovation Groups

My first take on the most important bits for Canadian biotech companies and investors:

1) Looks like Section 116 will stay dead this time!

2) Better for research funding, with Genome Canada, NSERC, CIHR, SSHRC coming out much better than last year.  Grease?  Meet squeaky wheel.

3) Is this the end of the SIFT/SR&ED dealsLooks that way: Yes. Right now!

“Ensure that income trust conversions into corporations are subject to the same loss utilization rules that currently apply to similar transactions involving only corporations.”

Right now = today…

“[T]hese amendments apply to transactions undertaken after 4:00 p.m. Eastern Standard Time on March 4, 2010, other than transactions that the parties are obligated to complete pursuant to the terms of an agreement in writing between the parties entered into before that time.”

4) The new SMB Innovation Commercialization Program — looks like a made-here-bought-here initiative:

“a two-year pilot initiative through which federal departments and agencies will adopt and demonstrate the use of innovative prototype products and technologies developed by small and medium-sized businesses. Budget 2010 provides $40 million over two years to support up to 20 demonstration projects. To help small and medium-sized businesses take advantage of this initiative, the Government will organize regional trade shows so that companies can showcase their innovative concepts to federal departments. Further details regarding this initiative will be announced later in the spring of 2010.”

5) Some administrative improvements to SR&ED credits:

“In addition, as announced in January 2010, the CRA will begin to report quarterly, through its website, on the time it takes to review an SR&ED claim from start to finish. A new manual for CRA reviewers will become effective on April 1, 2010. This manual will emphasize how the CRA will work closely with claimants so that they may better understand the SR&ED program requirements and process.”

CIHR’s Canadian Health Research Awards and Prix Galien Canada Name 2009 Awardees

Awardees were announced today for CIHR’s Canadian Health Research Awards and for the Prix Galien Canada. It’s great to see awards that cross such a broad spectrum: basic and applied research; and molecular and population-based approaches.

The CIHR awardees are:

  • Dr. Nahum Sonenberg at McGill for his pioneering work on translation control mechanisms, opening the door to new treatments for diseases such as cancer and HIV/AIDS.
  • Dr. Michael Boyle at McMaster for his work on the relationship between children’s health and their environment, and for his work to improve research techniques and methodology in this area.
  • Dr. Lynne-Marie Postovit at Western for her work on how oxygen levels and other micro-environmental signals influence the behaviour and development of normal and cancer stem cells.

The Prix Galien Canada consists of two prizes — the Research Award and the Innovative Product Award:

  • Dr. Donald Weaver at Dalhousie  is receiving the Prix Galien Research Award for his efforts to design novel drug therapies to treat chronic neurological disorders such as epilepsy and Alzheimer’s.
  • Pfizer Canada Inc. is receiving the Prix Galien for Innovative Product for Champix™ (pdf), the first in a new class of prescription medications to help people stop smoking.

Congratulations to the winners! Hope everyone had a good time in Ottawa tonight.

Bookmark and Share

PubMed Central Comes to Canada (or vice-versa?)

PumMed Central LogoIf you ever read scientific publications, but you don’t have institutional journal subscriptions, you definitely know and love PubMed Central, the U.S. National Library of Medicine’s (NLM) online repository of free-access full-text papers. Well, get ready for So You Think You Can Publish Canada PubMed Central Canada!

CIHR and the NRC’s Canada Institute for Scientific and Technical Information are partnering with NLM to establish PMC Canada, which follows UK PubMed Central (UKPMC) as PubMed Central expands internationally:

“PMC Canada will be a national digital repository of peer-reviewed health and life sciences literature, including research resulting from CIHR funding. This searchable Web-based repository will be permanent, stable and freely accessible. … PMC Canada will include a manuscript submission system to enable CIHR-funded researchers to deposit articles that are accepted for publication by peer reviewed journals.”

This initiative has been under way for some time, but it serves as a way to implement CIHR’s recently announced Policy on Access to Research Outputs, under which grant recipients are required to ensure that their peer reviewed publications are freely accessible online within six months of publication.  The NIH has a similar policy, with a 12-month window.

Bookmark and Share

Follow

Get every new post delivered to your Inbox.

Join 125 other followers